Literature DB >> 25687558

ROCK and Rho: Promising therapeutic targets to ameliorate pulmonary fibrosis.

David W H Riches1, Donald S Backos2, Elizabeth F Redente3.   

Abstract

This commentary highlights the article by Sisson et al, which establishes the importance of the myocardin-related transcription factor/serum response factor signaling pathway as a therapeutic target in the management of fibrotic lung disease.
Copyright © 2015 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25687558      PMCID： PMC4380839          DOI： 10.1016/j.ajpath.2015.01.005

Source DB:  PubMed          Journal:  Am J Pathol        ISSN： 0002-9440            Impact factor:   4.307


  25 in total

1.  Mechanism of fibrotic cardiomyopathy in mice expressing truncated Rho-associated coiled-coil protein kinase 1.

Authors:  Xiangsheng Yang; Qi Li; Xi Lin; Yanlin Ma; Xiaojing Yue; Zhenyin Tao; Fen Wang; Wallace L Mckeehan; Lei Wei; Robert J Schwartz; Jiang Chang
Journal:  FASEB J       Date:  2012-01-25       Impact factor: 5.191

Review 2.  Idiopathic pulmonary fibrosis: natural history and prognosis.

Authors:  Paul W Noble
Journal:  Clin Chest Med       Date:  2006-03       Impact factor: 2.878

3.  Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental pulmonary fibrosis.

Authors:  Yong Zhou; Xiangwei Huang; Louise Hecker; Deepali Kurundkar; Ashish Kurundkar; Hui Liu; Tong-Huan Jin; Leena Desai; Karen Bernard; Victor J Thannickal
Journal:  J Clin Invest       Date:  2013-02-22       Impact factor: 14.808

4.  Myocardin-related transcription factor-A complexes activate type I collagen expression in lung fibroblasts.

Authors:  Larry L Luchsinger; Cassandra A Patenaude; Barbara D Smith; Matthew D Layne
Journal:  J Biol Chem       Date:  2011-11-02       Impact factor: 5.157

5.  An essential role for resident fibroblasts in experimental lung fibrosis is defined by lineage-specific deletion of high-affinity type II transforming growth factor β receptor.

Authors:  Rachel K Hoyles; Emma C Derrett-Smith; Korsa Khan; Xu Shiwen; Sarah L Howat; Athol U Wells; David J Abraham; Christopher P Denton
Journal:  Am J Respir Crit Care Med       Date:  2010-08-13       Impact factor: 21.405

6.  X-linked inhibitor of apoptosis regulates lung fibroblast resistance to Fas-mediated apoptosis.

Authors:  Iyabode O Ajayi; Thomas H Sisson; Peter D R Higgins; Adam J Booth; Rommel L Sagana; Steven K Huang; Eric S White; Jessie E King; Bethany B Moore; Jeffrey C Horowitz
Journal:  Am J Respir Cell Mol Biol       Date:  2013-07       Impact factor: 6.914

Review 7.  Rho-associated coiled-coil kinase (ROCK) signaling and disease.

Authors:  Alice V Schofield; Ora Bernard
Journal:  Crit Rev Biochem Mol Biol       Date:  2013-04-19       Impact factor: 8.250

8.  Cellular FLICE-like inhibitory protein deviates myofibroblast fas-induced apoptosis toward proliferation during lung fibrosis.

Authors:  Regina Golan-Gerstl; Shulamit B Wallach-Dayan; Philip Zisman; Wellington V Cardoso; Ronald H Goldstein; Raphael Breuer
Journal:  Am J Respir Cell Mol Biol       Date:  2012-05-10       Impact factor: 6.914

9.  Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.

Authors:  Luca Richeldi; Roland M du Bois; Ganesh Raghu; Arata Azuma; Kevin K Brown; Ulrich Costabel; Vincent Cottin; Kevin R Flaherty; David M Hansell; Yoshikazu Inoue; Dong Soon Kim; Martin Kolb; Andrew G Nicholson; Paul W Noble; Moisés Selman; Hiroyuki Taniguchi; Michèle Brun; Florence Le Maulf; Mannaïg Girard; Susanne Stowasser; Rozsa Schlenker-Herceg; Bernd Disse; Harold R Collard
Journal:  N Engl J Med       Date:  2014-05-18       Impact factor: 91.245

10.  Fasudil, a Rho-kinase inhibitor, attenuates bleomycin-induced pulmonary fibrosis in mice.

Authors:  Chunguo Jiang; Hui Huang; Jia Liu; Yanxun Wang; Zhiwei Lu; Zuojun Xu
Journal:  Int J Mol Sci       Date:  2012-07-04       Impact factor: 6.208
View more
  9 in total

1.  Microbes Are Associated with Host Innate Immune Response in Idiopathic Pulmonary Fibrosis.

Authors:  Yong Huang; Shwu-Fan Ma; Milena S Espindola; Rekha Vij; Justin M Oldham; Gary B Huffnagle; John R Erb-Downward; Kevin R Flaherty; Beth B Moore; Eric S White; Tong Zhou; Jianrong Li; Yves A Lussier; MeiLan K Han; Naftali Kaminski; Joe G N Garcia; Cory M Hogaboam; Fernando J Martinez; Imre Noth
Journal:  Am J Respir Crit Care Med       Date:  2017-07-15       Impact factor: 21.405

2.  AMP-activated protein kinase/myocardin-related transcription factor-A signaling regulates fibroblast activation and renal fibrosis.

Authors:  Yuguo Wang; Li Jia; Zhaoyong Hu; Mark L Entman; William E Mitch; Yanlin Wang
Journal:  Kidney Int       Date:  2017-07-21       Impact factor: 10.612

3.  Releasing Tensin.

Authors:  Jeffrey C Horowitz
Journal:  Am J Respir Cell Mol Biol       Date:  2017-04       Impact factor: 6.914

Review 4.  Mechanisms for the Resolution of Organ Fibrosis.

Authors:  Jeffrey C Horowitz; Victor J Thannickal
Journal:  Physiology (Bethesda)       Date:  2019-01-01

Review 5.  ROCK2, a critical regulator of immune modulation and fibrosis has emerged as a therapeutic target in chronic graft-versus-host disease.

Authors:  Alexandra Zanin-Zhorov; Bruce R Blazar
Journal:  Clin Immunol       Date:  2021-08-14       Impact factor: 10.190

6.  ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease.

Authors:  Madan Jagasia; Aleksandr Lazaryan; Carlos R Bachier; Amandeep Salhotra; Daniel J Weisdorf; Behyar Zoghi; James Essell; Laurie Green; Olivier Schueller; Jeegar Patel; Alexandra Zanin-Zhorov; Jonathan M Weiss; Zhongming Yang; David Eiznhamer; Sanjay K Aggarwal; Bruce R Blazar; Stephanie J Lee
Journal:  J Clin Oncol       Date:  2021-04-20       Impact factor: 50.717

7.  ROCK2 inhibition attenuates profibrogenic immune cell function to reverse thioacetamide-induced liver fibrosis.

Authors:  Christina Nalkurthi; Wayne A Schroder; Michelle Melino; Katharine M Irvine; Melanie Nyuydzefe; Wei Chen; Jing Liu; Michele W L Teng; Geoffrey R Hill; Patrick Bertolino; Bruce R Blazar; Gregory C Miller; Andrew D Clouston; Alexandra Zanin-Zhorov; Kelli P A MacDonald
Journal:  JHEP Rep       Date:  2021-10-06

8.  Inhibition of ROCK ameliorates pulmonary fibrosis by suppressing M2 macrophage polarisation through phosphorylation of STAT3.

Authors:  Qingfang Li; Yuan Cheng; Zhe Zhang; Zhenfei Bi; Xuelei Ma; Yuquan Wei; Xiawei Wei
Journal:  Clin Transl Med       Date:  2022-10

9.  Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study.

Authors:  Corey Cutler; Stephanie J Lee; Sally Arai; Marcello Rotta; Behyar Zoghi; Aleksandr Lazaryan; Aravind Ramakrishnan; Zachariah DeFilipp; Amandeep Salhotra; Wanxing Chai-Ho; Rohtesh Mehta; Trent Wang; Mukta Arora; Iskra Pusic; Ayman Saad; Nirav N Shah; Sunil Abhyankar; Carlos Bachier; John Galvin; Annie Im; Amelia Langston; Jane Liesveld; Mark Juckett; Aaron Logan; Levanto Schachter; Asif Alavi; Dianna Howard; Harlan W Waksal; John Ryan; David Eiznhamer; Sanjay K Aggarwal; Jonathan Ieyoub; Olivier Schueller; Laurie Green; Zhongming Yang; Heidi Krenz; Madan Jagasia; Bruce R Blazar; Steven Pavletic
Journal:  Blood       Date:  2021-12-02       Impact factor: 25.476
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.